Critical Path Project

In cooperation with The Critical Path Institute headed up by Ray Woosley, academic researchers and other stakeholders, we are seeking to promote support for and participation in activities that advance the Critical Path Initiative. The challenge facing the world is disease, not unsafe medicines. Drug safety is critical, but it is a decision that should be based on individual risk factors identified using new tools, better science-based information and greater consumer control over health information.

We recently had a conference with over 100 journalists, scientists, and policymakers in attendance that looked at the media?s emphasis on the risks of medicines at the expense of a more balanced approach to coverage.

CMPI is now conducting research as to whether or not consumers will actually benefit from follow-on biologics compared to increased investment in new biologics. We are also holding a conference in Washington about alternatives to proposals to restrict patient and physician access to drugs as a way to limit drug risk contained in Institute of Medicine report and congressional FDA proposals. Our approach would rely on biomarkers based trials and more advanced health information technology in the post market. This latter activity is being conducted in cooperation with patient groups and the Critical Path Institute.
Sign Up for Our Email Newsletter

RECENT NEWS

New Report Demonstrates How Hospitals, Pharmacies & PBMs Exploit the Federal 340B Drug Program to the Harm of Disadvantaged Patients
  • CMPI
  • 09/09/2022 12:00 AM

New Report Demonstrates How Hospitals, Pharmacies & PBMs Exploit the Federal 340B Drug Program to the Harm of Disadvantaged Patients

Nation’s largest hospitals, pharmacy benefit managers (PBMs), and pharmacies abuse drug discount program to pocket saving...  Read more

Peter Pitts on CDC reorganization proposal

Peter Pitts on CDC reorganization proposal

Peter Pitts joins NEWSY to discuss proposed CDC changes...  Read more

Why the FTC is Investigating Pharmacy Benefit Managers

Why the FTC is Investigating Pharmacy Benefit Managers

In money matters, U.S. regulators are investigating claims by PBMs who say they save you money on prescriptions....  Read more

DRUGWONKS BLOG